The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
Earnings Scheduled For November 9, 2021
Companies Reporting Before The Bell
• Imara (NASDAQ:IMRA) is projected to report earnings for its third quarter.
• KT (NYSE:KT) is projected to report earnings for its third quarter.
Barclays Maintains Overweight on Ligand Pharmaceuticals, Raises Price Target to $180
Barclays analyst Balaji Prasad maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Overweight and raises the price target from $174 to $180.
Why Digital Turbine’s Stock Is Trading Higher Today
Digital Turbine Inc (NASDAQ: APPS) is trading higher Tuesday after it was announced the company is set to join the S&P MidCap 400.
Digital Turbine To Be Added To S&P MidCap 400 Index; Gets Analyst Upgrades
Media and mobile communications company Digital Turbine Inc (NASDAQ:APPS) will replace Ligand Pharmaceuticals Inc (NASDAQ:LGND) in the S&P…
The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 26)
S&P Dow Jones Indices Announces ‘Performance Food Group & Digital Turbine Set to Join S&P MidCap 400; TreeHouse Foods & Ligand Pharmaceuticals to Join S&P SmallCap 600’
https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20210830-1442976/1442976_4cbb64core44.pdf
Ligand Pharma Partner Gloria Biosciences Receives Approval In China For Zimberelimab For Treatment Of Recurrent, Refractory Classical Hodgkin’s Lymphoma
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its partner Gloria Biosciences (GloriaBio) has received approval from China’s National Medical Products Administration (NMPA) for zimberelimab
Sermonix Pharmaceuticals Completes Enrollment of Phase 2 ELAINE 1 Randomized Clinical Trial Assessing Efficacy Of Oral Lasofoxifene Versus Intramuscular Fulvestrant; NOTE: Co. Licensed Lasofoxifene From Ligand
Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to treat ESR1-mutated metastatic breast and gynecological cancers, today announced that it has completed
What To Know About Rand Paul Failing To Disclose Gilead Stock Purchase For 16 Months
Stock transactions by members of the U.S. Congress and their spouses have been a hot topic over the last several years. A transaction disclosed late Wednesday is drawing heavy scrutiny from the public.